Very good response rates, including high complete response (CR) rates, were reported in patients with non-Hodgkin lymphoma (NHL) who were treated with a chimeric antigen receptor (CAR) T-cell protocol that included several features designed to maximize immunotherapeutic effects while minimizing toxicity.
In this protocol, CAR T cells were administered in a 1:1 ratio of CD4+ and CD8+ T cells after a lymphodepletion regimen that included cyclophosphamide and fludarabine. In patients who tolerated